UCB wins FDA approvals in plaque psoriasis and gMG, unlocking blockbuster opportunities

UCB’s treat­ment can­di­dates for plaque pso­ri­a­sis and gen­er­al­ized myas­the­nia gravis have both bagged ap­provals in the US, ex­pand­ing cur­rent mar­ket op­por­tu­ni­ties and open­ing up new ones with block­buster po­ten­tial, ac­cord­ing to an­a­lysts.

First off, the Bel­gian drug­mak­er’s Bimzelx, al­so known as bimek­izum­ab, to­day won a long-await­ed FDA ap­proval for mod­er­ate to se­vere plaque pso­ri­a­sis pa­tients who are can­di­dates for sys­temic ther­a­py or pho­tother­a­py. Plaque pso­ri­a­sis af­fects more than 7.5 mil­lion adults in the US, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.